Verve Therapeutics (NASDAQ:VERV) Stock Price Up 5.6% - What's Next?

Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) shares rose 5.6% on Wednesday . The stock traded as high as $7.47 and last traded at $7.66. Approximately 41,799 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 1,718,185 shares. The stock had previously closed at $7.25.

Analysts Set New Price Targets

VERV has been the subject of a number of recent analyst reports. Canaccord Genuity Group upped their target price on Verve Therapeutics from $29.00 to $32.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th. HC Wainwright dropped their target price on shares of Verve Therapeutics from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Finally, Royal Bank of Canada cut their target price on shares of Verve Therapeutics from $20.00 to $17.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th.

Verve Therapeutics Price Performance

The firm's 50 day moving average price is $6.07 and its 200-day moving average price is $5.83. The firm has a market cap of $644.52 million, a price-to-earnings ratio of -3.11 and a beta of 1.68.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share for the quarter, topping analysts' consensus estimates of ($0.70) by $0.11. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business had revenue of $6.87 million for the quarter, compared to the consensus estimate of $2.75 million. During the same period last year, the business earned ($0.72) earnings per share. The firm's revenue for the quarter was up 120.2% compared to the same quarter last year. Analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Institutional Trading of Verve Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VERV. GAMMA Investing LLC boosted its holdings in Verve Therapeutics by 189.7% during the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock valued at $34,000 after purchasing an additional 3,964 shares in the last quarter. Creative Planning acquired a new stake in Verve Therapeutics in the 3rd quarter valued at about $50,000. PFG Investments LLC acquired a new stake in shares of Verve Therapeutics in the 3rd quarter valued at $53,000. Erste Asset Management GmbH bought a new stake in Verve Therapeutics during the 3rd quarter worth about $56,000. Finally, Impact Partnership Wealth LLC acquired a new position in Verve Therapeutics in the fourth quarter valued at approximately $70,000. Institutional investors own 97.11% of the company's stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.